Chapter 6 190 Supplementary materials 6 6.1. Hormone form and dosage The table below displays the form and dosage of GAHT used by the study participants, at the start of GAHT (e.g. after the baseline measurement) and at the 3-month follow up. Table S6.1. Hormone formulation prescribed at the start of GAHT and 3 month follow-up. Transmasculine participants (n=38) Transfeminine participants (n=35) Measurement Start of GAHT n=36 At 3 month follow-up n=26 Start of GAHT n=32 At 3 month follow-up n=24 Cycle regulation use (n, %) Progestin only – oral 4 (11%) 3 (12%) - - Progestin only – non-oral methods 1. 8 (22%) 3 (12%) - - Estradiol and progestin – combined oral contraceptives 6 (17%) 0 (0%) - - None 18 (50%) 6 (23%) - - Testosterone form (n, %) Transdermal 32 (89%) 19 (73%) - - Intramuscular – short-acting (esters) 4 (11%) 2 (8%) - - Intramuscular – long-acting (undecanoate) 0 (0%) 5 (20%) - - Estrogen form (n, %) Oral - - 17 (53%) 14 (46%) Transdermal – gel - - 3 (9%) 3 (13%) Transdermal – spray - - 0 (0%) 0 (0%) Transdermal – patches - - 12 (38%) 7 (29%) Anti-androgen form (n, %) GnRH analogues – short-acting - - 25 (78%) 13 (54%) GnRH analogues – long-acting - - 4 (13%) 8 (33%) Cyproterone actate - - 3 (9%) 3 (13%) 1. Methods include hormonal intrauterine devices, intramuscular injections, progestin implants. 6.2. Smartsleep mode The table below displays the outcomes stratified by sleep device setting and the estimated differences between the inactive and the active mode. Analyses show no significant differences between the active and inactive mode of the device.
RkJQdWJsaXNoZXIy MTk4NDMw